UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

Annals of oncology, 2021-05, Vol.32 (5), p.661-672

2021

Volltextzugriff (PDF)

Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

Oncogene, 2016-05, Vol.35 (21), p.2687-2697

2016

Volltextzugriff (PDF)

Alternate sunitinib schedules in patients with metastatic renal cell carcinoma

Annals of oncology, 2015-07, Vol.26 (7), p.1300-1304

2015

Volltextzugriff (PDF)

Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis

Oncogene, 2015-05, Vol.34 (19), p.2450-2460

2015

Volltextzugriff (PDF)

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors

European journal of cancer (1990), 2019-06, Vol.114, p.67-75

2019

Volltextzugriff (PDF)

Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis

European journal of cancer (1990), 2018-11, Vol.104, p.188-194

2018

Volltextzugriff (PDF)

High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma

Oncogene, 2016-03, Vol.35 (12), p.1565-1574

2016

Volltextzugriff (PDF)

Instrumentarium und Lagerungstechnik bei unfallchirurgischen Operationen

E. Jonasch, H. Arzinger-Jonasch

2019

Volltextzugriff (PDF)

Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL

Oncogene, 2017-06, Vol.36 (24), p.3450-3463

2017

Volltextzugriff (PDF)

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma

Annals of oncology, 2017-04, Vol.28 (4), p.804-808

2017

Volltextzugriff (PDF)

An open-label phase II study to evaluate PT2977 for the treatment of von hippel-lindau disease associated renal cell carcinoma

Annals of oncology, 2018-10, Vol.29, p.viii328-viii328

2018

Volltextzugriff (PDF)

Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules

Oncogene, 2014-06, Vol.33 (26), p.3463-3472

2014

Volltextzugriff (PDF)

Site-specific activation of AKT protects cells from death induced by glucose deprivation

Oncogene, 2014-02, Vol.33 (6), p.745-755

2014

Volltextzugriff (PDF)

Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay

Annals of oncology, 2022-11, Vol.33 (11), p.1204-1206

2022

Volltextzugriff (PDF)

Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al

Annals of oncology, 2021-09, Vol.32 (9), p.1194-1197

2021

Volltextzugriff (PDF)

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma

Annals of oncology, 2012-01, Vol.23 (1), p.46-52

2012

Volltextzugriff (PDF)

Pilot trial of sunitinib therapy in patients with von Hippel–Lindau disease

Annals of oncology, 2011-12, Vol.22 (12), p.2661-2666

2011

Volltextzugriff (PDF)

Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma

Annals of oncology, 2010-08, Vol.21 (8), p.1599-1606

2010

Volltextzugriff (PDF)

Gevokizumab, an interleukin-1β (IL-1β) monoclonal antibody (mAb), in metastatic colorectal cancer (mCRC), metastatic gastroesophageal cancer (mGEC) and metastatic renal cell carcinoma (mRCC): “first-in-cancer” phase Ib study

Annals of oncology, 2019-07, Vol.30, p.iv77-iv78

2019

Volltextzugriff (PDF)

Instrumentarium und Lagerungstechnik bei unfallchirurgischen Operationen

2019

Volltextzugriff (PDF)

Renal cell carcinoma

BMJ (Online), 2014-11, Vol.349 (nov10 11), p.g4797-g4797

2014

Volltextzugriff (PDF)

Real-world effectiveness of pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma (PRINCIPAL study)

Annals of oncology, 2018-10, Vol.29, p.viii313-viii313

2018

Volltextzugriff (PDF)

Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function

Oncogene, 2016-09, Vol.35 (38), p.4973-4980

2016

Volltextzugriff (PDF)

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies

European journal of cancer (1990), 2013-10, Vol.49 (15), p.3169-3175

2013

Volltextzugriff (PDF)

Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy

Annals of oncology, 2011-05, Vol.22 (5), p.1048-1053

2011

Volltextzugriff (PDF)

1 – 25 von 364

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(246)
Mit Volltextzugriff
(242)

Publikationsform

Sprache

Englisch
(248)
Deutsch
(136)
Italienisch
(1)
Latein
(1)

Erscheinungsjahr

n.n

Thema

Humans
(150)
Science & Technology
(86)
Life Sciences & Biomedicine
(83)
Male
(54)
Oncology
(54)
Female
(53)
Old Medline
(47)
Middle Aged
(45)
Adult
(39)
Aged
(34)
Kidney Neoplasms - Pathology
(32)
Carcinoma, Renal Cell - Drug Therapy
(31)
Carcinoma, Renal Cell - Pathology
(30)
Kidney Neoplasms - Drug Therapy
(29)
Renal Cell Carcinoma
(26)
Biological And Medical Sciences
(25)
Medical Sciences
(25)
Treatment Outcome
(24)
Knee Joint
(22)
Retrospective Studies
(22)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

Alternate sunitinib schedules in patients with metastatic renal cell carcinoma

Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors

Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis

High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma

Instrumentarium und Lagerungstechnik bei unfallchirurgischen Operationen

Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma

An open-label phase II study to evaluate PT2977 for the treatment of von hippel-lindau disease associated renal cell carcinoma

Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules

Site-specific activation of AKT protects cells from death induced by glucose deprivation

Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay

Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma

Pilot trial of sunitinib therapy in patients with von Hippel–Lindau disease

Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma

Gevokizumab, an interleukin-1β (IL-1β) monoclonal antibody (mAb), in metastatic colorectal cancer (mCRC), metastatic gastroesophageal cancer (mGEC) and metastatic renal cell carcinoma (mRCC): “first-in-cancer” phase Ib study

Instrumentarium und Lagerungstechnik bei unfallchirurgischen Operationen

Renal cell carcinoma

Real-world effectiveness of pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma (PRINCIPAL study)

Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies

Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy

Suchergebnisse filtern